Making an Impact

Aerial shot of the HHMI's Maryland headquarters. On a pristine 23-acre campus in Maryland located just a few miles from the National Institutes of Health, a handful of scientists decides how America's richest privately held biomedical research organization should distribute more than $500 million in funding annually. But the Howard Hughes Medical Institute, perhaps America's most prestigious patron of biomedical research, has undergone a changing of the guard at its Chevy Chase headquarters in t

Written byEugene Russo
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share


Aerial shot of the HHMI's Maryland headquarters.
On a pristine 23-acre campus in Maryland located just a few miles from the National Institutes of Health, a handful of scientists decides how America's richest privately held biomedical research organization should distribute more than $500 million in funding annually. But the Howard Hughes Medical Institute, perhaps America's most prestigious patron of biomedical research, has undergone a changing of the guard at its Chevy Chase headquarters in the past year--and, as a result, a slight change in funding philosophy as well.

Last January, Nobel laureate Thomas Cech, an RNA researcher at the University of Colorado in Boulder and an HHMI investigator since 1988, became the new HHMI president, replacing Purnell Choppin. Gerry Rubin, an HHMI investigator and professor of genetics at the University of California, Berkeley, who led efforts to sequence the Drosophila genome, came on as vice president for biomedical research. And ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies